Physician profile
Jean E Stalcup
NPI 1104532811
$632.72
in general payments reported to CMS, 2019-2025
14 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $260 · 2024: $95.51 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $199.85 | 2023-2025 | Nemluvio, Epsolay, Dysport |
| Sun Pharmaceutical Industries INC. | $143.29 | 2023-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $37.37 | 2024-2025 | |
| Incyte Corporation | $36.31 | 2023 | Opzelura |
| Pfizer INC. | $34.57 | 2023 | |
| Ucb, INC. | $32.20 | 2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $26.95 | 2025 | |
| Organon LLC | $21.59 | 2025 | |
| Almirall LLC | $20.49 | 2025 | Seysara |
| Regeneron Healthcare Solutions, INC. | $18.70 | 2024 | Dupixent |
| Arcutis Biotherapeutics, INC. | $16.99 | 2025 | Zoryve |
| Botanix Sb INC | $15.66 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $15.25 | 2024 | Sotyktu |
| Kowa Pharmaceuticals America, INC. | $13.50 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Stalcup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.